Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Receivables (2019 - 2025)

X4 Pharmaceuticals' Receivables history spans 5 years, with the latest figure at $573000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 66.49% year-over-year to $573000.0; the TTM value through Dec 2025 reached $573000.0, down 66.49%, while the annual FY2025 figure was $573000.0, 66.49% down from the prior year.
  • Receivables reached $573000.0 in Q4 2025 per XFOR's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.9 million in Q2 2025 to a low of $562000.0 in Q4 2023.
  • Average Receivables over 3 years is $1.2 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Receivables: surged 204.27% in 2024, then plummeted 66.49% in 2025.
  • A 3-year view of Receivables shows it stood at $562000.0 in 2023, then soared by 204.27% to $1.7 million in 2024, then crashed by 66.49% to $573000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Receivables are $573000.0 (Q4 2025), $1.6 million (Q3 2025), and $1.9 million (Q2 2025).